Recombinant Human GM-CSF (CSF2) | Z100279

abm | Recombinant Human GM-CSF (CSF2) | Z100279

GM-CSF is a monomeric protein of 127 amino acids with two glycosylation sites. The protein is synthesized as a precursor of 144 amino acids, which included a hydrophobic secretory signal sequence at the amino terminal end. The sugar moiety is not required for the full spectrum of biological activities. Non-glycosylated and glycosylated GM-CSF show the same activities in vitro. Fully glycosylated GM-CSF is biologically more active in vivo than the non-glycosylated protein. This protein is secreted together with other factors by T cells and macrophages following cell activation by antigens or mitogens. Approximately 90% of the secreted colony stimulating activities are due to GM-CSF.

Functions:

The ED(50) as determined by the dose-dependent stimulation of the proliferation of human TF-1 cells is ≤ 0.1 ng/mL, corresponding to a specific activity of ≥ 1.0 x 10^7 units/mg.

Organism:

Human

Source:

E. coli

Alias:

GMCSF, Granulocyte-macrophage colony-stimulating factor, CSF-2, Molgramostin, Sargramostim, pluripoietin-alpha, Recombinant Human Granulocyte Macrophage Colony Stimulating Factor (CSF2)

Gene Symbol:

CSF2

Gene ID:

1437

Accession:

P04141

Formulation:

Human GM-CSF was lyophilized from a 0.2 μm filtered solution in PBS, pH 7.0.

Solubility:

A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.

Appearance:

Lyophilized Powder

Molecular Weight (kDa):

15

Molecular Weight 2 (kDA):

N/A

Molecular Weight 3 (kDA):

N/A

Purity:

>95% as determined by SDS-PAGE

Concentration:

<1.0 EU/μg of recombinant protein as determined by the LAL method.

Shipping Condition :

Ambient Temperature

Storage Condition:

The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.